# N99-02: Melphalan and Buthionine Sulfoximine

> **NCT00005835** · PHASE1 · COMPLETED · sponsor: **New Approaches to Neuroblastoma Therapy Consortium** · enrollment: 31 (actual)

## Conditions studied

- Neuroblastoma

## Interventions

- **DRUG:** buthionine sulfoximine
- **DRUG:** melphalan
- **PROCEDURE:** Peripheral blood stem cell infusion
- **OTHER:** Filgrastim

## Key facts

- **NCT ID:** NCT00005835
- **Lead sponsor:** New Approaches to Neuroblastoma Therapy Consortium
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-08
- **Primary completion:** 2014-12
- **Final completion:** 2016-04
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2023-04-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00005835

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00005835, "N99-02: Melphalan and Buthionine Sulfoximine". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00005835. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*